News
TNXP
0.2025
-0.83%
-0.0017
Biotech Alert: Searches spiking for these stocks today
TipRanks · 1d ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 1d ago
Why Keysight Technologies Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
Benzinga · 2d ago
Tonix Pharmaceuticals Reports Positive Phase 3 Results for TNX-102 SL in Fibromyalgia, Submits NDA to FDA
Barchart · 4d ago
Tonix Pharmaceuticals to Present at the Winter 2024 Investor Summit Virtual
Barchart · 4d ago
Tonix Pharmaceuticals presents data, analyses of TNX-102 SL effects
TipRanks · 4d ago
Press Release: Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting
Dow Jones · 4d ago
Press Release: Tonix Pharmaceuticals Presented -2-
Dow Jones · 4d ago
Weekly Report: what happened at TNXP last week (1111-1115)?
Weekly Report · 4d ago
First mpox case linked to African outbreak reported in U.S.
Seeking Alpha · 5d ago
Tonix Pharma Reveals Promising TNX-801 Vaccine Data
TipRanks · 11/13 14:29
Tonix Pharmaceuticals announces publication of study on tolerability of TNX-801
TipRanks · 11/13 14:10
Tonix Pharmaceuticals Publishes Peer-Reviewed Publication In mSphere Journal Highlighting Tolerability Of its Single-Dose Mpox And Smallpox Vaccine Candidate TNX-801, In Immune-Compromised Animals
Benzinga · 11/13 14:07
TONIX PHARMACEUTICALS ANNOUNCES PEER-REVIEWED PUBLICATION IN MSPHERE JOURNAL HIGHLIGHTING THE TOLERABILITY OF COMPANY’S SINGLE-DOSE MPOX AND SMALLPOX VACCINE CANDIDATE TNX-801, IN IMMUNE-COMPROMISED ANIMALS
Reuters · 11/13 14:05
TONIX PHARMACEUTICALS HOLDING CORP - TNX-801 TOLERABILITY IN IMMUNE-COMPROMISED ANIMALS SUPPORTS CLINICAL DEVELOPMENT
Reuters · 11/13 14:05
Based on the provided financial report articles, I generated the title for the article: "Quarterly Report for the Three Months Ended September 30, 2024" Please note that the title may not be exact, as the provided text does not contain a clear title. However, based on the content and format of the report, I inferred the title to be the above-mentioned one.
Press release · 11/13 04:32
Tonix Pharmaceuticals Holding Corp reports results for the quarter ended September 30 - Earnings Summary
Reuters · 11/12 15:27
Tonix Pharmaceuticals GAAP EPS of -$0.23 beats by $3.65, revenue of $2.82M misses by $0.33M
Seeking Alpha · 11/12 13:21
*Tonix Pharmaceuticals 3Q Research and Development Expenses $9.1M >TNXP
Dow Jones · 11/12 13:10
Press Release: Tonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights
Dow Jones · 11/12 13:01
More
Webull provides a variety of real-time TNXP stock news. You can receive the latest news about Tonix Pharmaceut through multiple platforms. This information may help you make smarter investment decisions.
About TNXP
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include Tonmya (TNX-102 SL), TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801 and TNX-1800. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.